Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 14/20 | 0.72 |
| ▸ | DDB1 | Q16531 | 8/20 | 0.72 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22623667 | 1.00 | CRBN (0.72) | CRBNDDB1PKMMAPTRECQL | |
| SCHEMBL22623824 | 0.84 | CRBN (0.68) | CRBNDDB1PKMALDH1A1KMT2A | |
| SCHEMBL6298788 | 0.84 | CRBN (0.51) | CRBNDDB1PKMMAPTRECQL | |
| SCHEMBL22612100 | 0.84 | CRBN (1.00) | CRBNDDB1KMT2A | |
| SCHEMBL22623720 | 0.75 | CRBN (0.43) | CRBNDDB1MAPTRECQLALDH1A1 | |
| SCHEMBL20812782 | 0.75 | CRBN (0.56) | CRBNDDB1PKMALDH1A1TSHR | |
| SCHEMBL28542516 | 0.74 | CRBN (0.48) | CRBNDDB1MAPTRECQLALDH1A1 | |
| SCHEMBL10879274 | 0.74 | RAB9A (0.47) | CRBNDDB1MAPTALDH1A1TSHR | |
| SCHEMBL20812472 | 0.74 | CRBN (0.54) | CRBNDDB1MAPT | |
| SCHEMBL25905416 | 0.72 | CRBN (0.51) | CRBNDDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234950-A1 | CRBN LIGANDS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-07-27 | — | — | US | disclosed |
| US-20230234950-A1 | CRBN LIGANDS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-07-27 | — | — | US | disclosed |
| US-20200347045-A1 | CRBN LIGANDS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2020-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234950-A1 | CRBN LIGANDS AND USES THEREOF | CRBN, CRKL, ERBB3 | CRBN 1/4885DDB1 304/4885PKM 3383/4885 |
| US-20200347045-A1 | CRBN LIGANDS AND USES THEREOF | CRBN, CRKL, ERBB3 | CRBN 1/4885DDB1 304/4885PKM 3383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.